Key result
Aldoxorubicin is a novel agent developed to treat soft tissue sarcomas with potentially less cardiotoxicity than doxorubicin.
Aldoxorubicin is a novel anthracycline derivative that may offer efficacy in soft tissue sarcoma with reduced cardiotoxicity compared to standard doxorubicin.
Aldoxorubicin may reduce cardiotoxicity in soft tissue sarcoma; leaves open need for randomized confirmation of efficacy.
Soft tissue sarcomas are a group of rare tumors of mesenchymal origin, and account for less than 1% of all cancers. The most commonly used drug for the treatment of soft tissue sarcoma is anthracycline chemotherapeutic agent, doxorubicin. The major limitation for doxorubicin is cardiotoxicity. Hence, to overcome this limitation and to increase efficacy, aldoxorubicin was developed, which has demonstrated activity in soft tissue sarcomas without much cardiotoxicity. In this review article, we discuss mechanism of action, pharmacokinetics, preclinical studies, clinical trial data and safety profile of aldoxorubicin and its potential applicability in the future of sarcoma treatment.
No takes yet. Share an insight, caveat, or question.
Seetharam et al. (2018) conducted a review in Advanced Soft Tissue Sarcoma. Aldoxorubicin was evaluated. Aldoxorubicin is a novel agent developed to treat soft tissue sarcomas with potentially less cardiotoxicity than doxorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: